SCHEMBL2670396

SCHEMBL2670396

COc1[c]ccc2c(=O)c(C(=O)O)cn(C3CC3)c12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 5/20 0.52
TOP2A P11388 6/20 0.45
TOP2B Q02880 6/20 0.45
GSK3B P49841 2/20 0.45
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 2/20 0.44
POLB P06746 2/20 0.44
OPRM1 P35372 2/20 0.44
PRKD3 O94806 1/20 0.44
ALOX15 P16050 1/20 0.44
CLK2 P49760 1/20 0.44
CLK4 Q9HAZ1 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CHRM2 P08172 1/20 0.41
CHRM1 P11229 1/20 0.41
OPRD1 P41143 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2670762 0.85 KCNH2 (0.46) KCNH2TOP2ATOP2BGSK3BKDM4E
SCHEMBL5619575 0.85 CYP3A4 (0.52) KCNH2TOP2ATOP2BGSK3BKDM4E
SCHEMBL2670237 0.85 CYP3A4 (0.52) KCNH2TOP2ATOP2BGSK3BKDM4E
SCHEMBL2670521 0.84 TOP2A (0.49) KCNH2TOP2ATOP2BGSK3BKDM4E
SCHEMBL2670640 0.81 TOP2A (0.50) KCNH2TOP2ATOP2BGSK3BKDM4E
SCHEMBL2670277 0.79 TOP2A (0.53) KCNH2TOP2ATOP2BGSK3BKDM4E
SCHEMBL2670552 0.79 TOP2A (0.47) KCNH2TOP2ATOP2BGSK3BKDM4E
SCHEMBL29793501 0.78 KDM4E (0.52) KCNH2TOP2ATOP2BGSK3BKDM4E
SCHEMBL4714374 0.78 KDM4E (0.52) KCNH2TOP2ATOP2BGSK3BKDM4E
SCHEMBL4747712 0.77 KCNH2 (0.61) KCNH2TOP2ATOP2BGSK3BKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130029977-A9 Fused substituted aminopyrrolidine derivative DAIICHI SANKYO COMPANY, LIMITED 2013-01-31 US claimed
US-20120108582-A1 Fused substituted aminopyrrolidine derivative DAIICHI SANKYO COMPANY, LIMITED 2012-05-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108582-A1 Fused substituted aminopyrrolidine derivative NQO2, QDPR, IL4I1 KCNH2 193/4885TOP2A 89/4885TOP2B 149/4885
US-20130029977-A9 Fused substituted aminopyrrolidine derivative NQO2, QDPR, IL4I1 KCNH2 193/4885TOP2A 89/4885TOP2B 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.